Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Capital Expenditures (2016 - 2025)

China Pharma Holdings' Capital Expenditures history spans 16 years, with the latest figure at $454.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 97.68% year-over-year to $454.0; the TTM value through Dec 2025 reached $59324.0, down 27.92%, while the annual FY2025 figure was $59324.0, 54.45% up from the prior year.
  • Capital Expenditures reached $454.0 in Q4 2025 per CPHI's latest filing, down from $611.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $415977.0 in Q3 2021 to a low of -$55964.0 in Q1 2023.
  • Average Capital Expenditures over 5 years is $56635.2, with a median of $2959.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: plummeted 4123.29% in 2023, then skyrocketed 331.74% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $7056.0 in 2021, then tumbled by 486.45% to -$27268.0 in 2022, then surged by 116.6% to $4527.0 in 2023, then soared by 331.74% to $19545.0 in 2024, then crashed by 97.68% to $454.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Capital Expenditures are $454.0 (Q4 2025), $611.0 (Q3 2025), and -$65.0 (Q2 2025).